Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by research analysts at Wells Fargo & Company to a “market perform” rating in a research note issued to investors on Thursday, The Fly reports. They presently have a $11.36 target price on the stock, down from their previous target price of $17.00. Wells Fargo & Company’s price objective suggests a potential downside of 17.68% from the stock’s current price.

A number of other research firms have also issued reports on TEVA. TheStreet lowered shares of Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. ValuEngine lowered shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research note on Wednesday, October 25th. Deutsche Bank AG reissued a “buy” rating and set a $28.00 target price (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, October 26th. Five research analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries Limited has a consensus rating of “Hold” and a consensus price target of $27.51.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.03). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.61 billion for the quarter, compared to the consensus estimate of $5.61 billion. During the same period in the prior year, the company earned $1.31 EPS. Teva Pharmaceutical Industries Limited’s quarterly revenue was up .8% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: “Wells Fargo & Company Downgrades Teva Pharmaceutical Industries Limited (TEVA) to Market Perform” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/02/wells-fargo-company-downgrades-teva-pharmaceutical-industries-limited-teva-to-market-perform.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Security National Bank of Sioux City Iowa IA increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after purchasing an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the last quarter. CIBC Asset Management Inc increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.3% during the 2nd quarter. CIBC Asset Management Inc now owns 65,534 shares of the company’s stock worth $2,177,000 after purchasing an additional 178 shares during the last quarter. Managed Account Services Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 1.4% during the 2nd quarter. Managed Account Services Inc. now owns 14,911 shares of the company’s stock worth $495,000 after purchasing an additional 211 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 3.6% during the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock worth $279,000 after purchasing an additional 294 shares during the last quarter. Institutional investors own 56.55% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

The Fly

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.